文献速递心力衰竭与心肌病

新发与急性失代偿心衰患者按射血分数分层的结局比较

Outcomes of de novo and acute decompensated heart failure patients according to ejection fraction.
PubMed 文献 · Heart · 2017-10-05

本研究基于韩国10所大学医院5625例连续急性心衰患者,纳入5414例有EF数据者,比较新发急性心衰与急性失代偿心衰患者中HFpEF、HFrEF及HFmrEF的预后差异。结果发现,在急性失代偿心衰中HFpEF预后优于HFrEF,但在新发急性心衰中两者全因死亡率无显著差异;HFmrEF的预后在住院后1年内与HFpEF相似,1年后与HFrEF相似。

要点

  • 新发急性心衰中HFpEF与HFrEF全因死亡率无显著差异。
  • 急性失代偿心衰中HFrEF死亡率显著高于HFpEF。
  • 急性失代偿心衰中HFmrEF的预后随时间变化,1年内接近HFpEF,1年后接近HFrEF。

核心结论

  • 在急性失代偿心衰患者中,HFpEF可能提示较HFrEF更好的预后,但在新发急性心衰中未见此差异。
  • 急性失代偿心衰中HFmrEF的预后在住院后1年内与HFpEF相似,1年后与HFrEF相似。

研究设计与样本

  • 研究为多中心连续队列,于2011年3月至2014年2月从10所大学医院纳入5625例连续急性心衰患者。
  • 共5414例(96.2%)有EF数据的患者入组,其中新发急性心衰2867例(53.0%),急性失代偿心衰2547例(47.0%)。
  • 入组患者按EF分层:HFpEF(EF≥50%)、HFrEF(EF<40%)、HFmrEF(40≤EF<50%)。

主要发现

  • 新发急性心衰中,HFpEF与HFrEF全因死亡率无显著差异(HFpEF vs HFrEF,206/744 (27.7%) vs 438/1631 (26.9%),HRadj 1.15,95% CI 0.96 to 1.38,p=0.14)。
  • 急性失代偿心衰中,HFrEF死亡率显著高于HFpEF(HFpEF vs HFrEF,245/613 (40.0%) vs 694/1551 (44.7%),HRadj 1.25,95% CI 1.06 to 1.47,p=0.007)。
  • 急性失代偿心衰中,HFmrEF 1年内死亡率显著低于HFrEF(HFmrEF vs HFrEF,88/383 (23.0%) vs 430/1551 (27.7%),HRadj 1.31,95% CI 1.03 to 1.65,p=0.03)。
  • 急性失代偿心衰中,HFmrEF 1年后死亡率显著高于HFpEF(HFmrEF vs HFpEF,83/295 (28.1%) vs 101/469 (21.5%),HRadj 0.70,95% CI 0.52 to 0.96,p=0.02)。

临床怎么用

  • 对急性失代偿心衰患者,应结合EF分层评估预后,HFrEF患者死亡风险较高。
  • 对急性失代偿心衰中HFmrEF患者,需关注1年后的死亡风险升高,加强长期随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: There are conflicting results among previous studies regarding the prognosis of heart failure with preserved ejection fraction (HFpEF) compared with heart failure with reduced ejection fraction (HFrEF). This study aimed to compare the outcomes of patients with de novo acute heart failure (AHF) or acute decompensated HF (ADHF) according to HFpEF (EF≥50%), or HFrEF (EF<40%) and to define the prognosis of patients with HF with mid-range EF (HFmrEF, 40≤EF<50%). METHODS: Between March 2011 and February 2014, 5625 consecutive patients with AHF were recruited from 10 university hospitals. A total of 5414 (96.2%) patients with EF data were enrolled, which consisted of 2867 (53.0%) patients with de novo and 2547 (47.0%) with ADHF. Each of the enrolled group was stratified by EF. RESULTS: In de novo, all-cause death rates were not significantly different between HFpEF and HFrEF (HFpEF vs HFrEF, 206/744 (27.7%) vs 438/1631 (26.9%), HRadj 1.15, 95% CI 0.96 to 1.38, p=0.14). However, among patients with ADHF, HFrEF had a significantly higher mortality rate compared with HFpEF (HFpEF vs HFrEF, 245/613 (40.0%) vs 694/1551 (44.7%), HRadj 1.25, 95% CI 1.06 to 1.47, p=0.007). Also, in ADHF, HFmrEF was associated with a significantly lower mortality rate within 1 year compared with HFrEF (HFmrEF vs HFrEF, 88/383 (23.0%) vs 430/1551 (27.7%), HRadj 1.31, 95% CI 1.03 to 1.65, p=0.03), but a significantly higher mortality rate after 1 year compared with HFpEF (HFmrEF vs HFpEF, 83/295 (28.1%) vs 101/469 (21.5%), HRadj 0.70, 95% CI 0.52 to 0.96, p=0.02). CONCLUSIONS: HFpEF may indicate a better prognosis compared with HFrEF in ADHF, but not in de novo AHF. For patients with ADHF, the prognosis associated with HFmrEF was similar to that of HFpEF within the first year following hospitalisation and similar to HFrEF 1 year after hospitalisation.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Choi KH, Lee GY, Choi JO, et al. Outcomes of de novo and acute decompensated heart failure patients according to ejection fraction. Heart. 2017. PMID: 28982721. doi:10.1136/heartjnl-2017-311813

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。